Humacyte (HUMA) Scheduled to Post Quarterly Earnings on Friday

Humacyte (NASDAQ:HUMA) is set to post its quarterly earnings results before the market opens on Friday, November 8th. Analysts expect Humacyte to post earnings of ($0.25) per share for the quarter.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Stock Performance

Humacyte stock traded down $0.04 during trading hours on Thursday, hitting $5.39. 305,824 shares of the stock traded hands, compared to its average volume of 2,336,031. The firm’s 50 day moving average price is $5.49 and its 200-day moving average price is $6.12. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41. The stock has a market capitalization of $643.30 million, a price-to-earnings ratio of -4.31 and a beta of 1.47. Humacyte has a 1 year low of $2.08 and a 1 year high of $9.97.

Wall Street Analysts Forecast Growth

HUMA has been the topic of a number of recent research reports. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. HC Wainwright upped their price target on shares of Humacyte from $6.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Benchmark reaffirmed a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $11.00.

Insider Buying and Selling

In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the completion of the transaction, the director now owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total transaction of $27,982.80. Following the transaction, the director now owns 40,276 shares in the company, valued at $217,490.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the completion of the sale, the director now directly owns 3,677,262 shares in the company, valued at $23,350,613.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,084,153 shares of company stock valued at $6,869,996. Corporate insiders own 11.20% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.